Figure 4

Distribution of comorbidities within each first major therapy class. Proportions are calculated based on the total number of patients reporting each comorbidity and plotted across the first therapy class. CKD, chronic kidney disease; GERD, gastro-oesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist.